120 - Treatment Conundrums, Not Always Black & White

Tuesday, October 21, 2025

10:30 AM - 11:45 AM US ET

Location: B308-B309

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Emily Spivak, MD, MHS (she/her/hers)

Professor of Medicine
Internal Medicine, Division of Infectious Diseases
University of Utah School of Medicine
Salt Lake City, UT, United States
MH

Marisa Holubar

Faculty(s)

Athena Hobbs, PharmD, BCIDP (she/her/hers)

Infectious Diseases Clinical Pharmacy Manager
Pharmacy
Cardinal Health
Dublin, OH, United States
Mary Joyce Wingler, PharmD

Clinical Pharmacy Specialist - Infectious Diseases/Antimicrobial Stewardship
Antimicrobial Stewardship Program
University of Mississippi Medical Center
Jackson, MS, United States
Whitney Hartlage, PharmD (she/her/hers)

Antimicrobial Stewardship Pharmacist
Harborview Medical Center, UW Medicine, Seattle, WA
Seattle, WA, United States

Disclosure(s):

Emily S. Spivak, MD, MHS: No financial relationships to disclose.

Athena L.V Hobbs, PharmD, BCIDP: No financial relationships to disclose.

Mary Joyce B. Wingler, PharmD: No financial relationships to disclose.

Whitney Hartlage, PharmD: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

review data evaluating the role of empiric atypical antibacterial coverage for community-acquired pneumonia;
compare patient outcomes when echinocandins or azole antifungals are used for initial therapy of candidemia;
identify the potential risks for neurological adverse events associated with cefepime and other beta-lactams and mitigation strategies.

Presentations:

10:30 AM - 10:55 AM US ET

Atypical Coverage for All Patients With Community-Acquired Pneumonia?
Speaker: Whitney Hartlage, PharmD (she/her/hers) – Harborview Medical Center, UW Medicine, Seattle, WA
10:55 AM - 11:20 AM US ET

Initial Echinocandin Therapy for All Candidemic Patients?
Speaker: Mary Joyce B. Wingler, PharmD – University of Mississippi Medical Center
11:20 AM - 11:45 AM US ET

Should I Avoid Cefepime and Other Beta-Lactams in My Elderly Patients Because of Risk for Neurotoxicity?
Speaker: Athena L.V Hobbs, PharmD, BCIDP (she/her/hers) – Cardinal Health